Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 5/20 | 0.52 |
| ▸ | NOS2 | P35228 | 5/20 | 0.52 |
| ▸ | NOS1 | P29475 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.44 |
| ▸ | CBLB | Q13191 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 2/20 | 0.37 |
| ▸ | GABRD | O14764 | 2/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.37 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.37 |
| ▸ | GABRE | P78334 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14041762 | 0.78 | UHRF1 (0.46) | NOS3NOS2NOS1KDM4EMEN1 | |
| SCHEMBL84401 | 0.77 | NOS3 (0.52) | NOS3NOS2NOS1KDM4EMEN1 | |
| SCHEMBL12181355 | 0.77 | NOS3 (0.44) | NOS3NOS2NOS1KDM4EMEN1 | |
| SCHEMBL9519789 | 0.76 | IDO1 (0.33) | NOS3NOS2NOS1CCR1CCR5 | |
| SCHEMBL14040228 | 0.76 | CCR1 (0.32) | NOS3NOS2NOS1CCR1CCR5 | |
| SCHEMBL31193096 | 0.76 | IDO1 (0.33) | NOS3NOS2NOS1CCR1CCR5 | |
| SCHEMBL4651277 | 0.76 | RECQL (0.38) | NOS3NOS2NOS1ROCK2ROCK1 | |
| SCHEMBL4322612 | 0.75 | NOS3 (0.50) | NOS3NOS2NOS1KDM4EMEN1 | |
| SCHEMBL514592 | 0.73 | NOS3 (0.48) | NOS3NOS2NOS1KDM4EMEN1 | |
| SCHEMBL13391128 | 0.73 | NOS3 (0.48) | NOS3NOS2NOS1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107667092-B | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | 诺华股份有限公司 | 2021-05-28 | — | — | CN | disclosed |
| US-10786492-B2 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2020-09-29 | — | — | US | disclosed |
| EP-3274344-B1 | FORMYLATED N-HETEROCYCLIC DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2019-04-24 | — | — | EP | disclosed |
| US-20190105309-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors. | NOVARTIS PHARMA AG (CH) | 2019-04-11 | — | — | US | disclosed |
| US-10189813-B2 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS AG (CH) | 2019-01-29 | — | — | US | disclosed |
| US-20180065951-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | NOVARTIS PHARMA AG (CH) | 2018-03-08 | — | — | US | disclosed |
| EP-3274344-A1 | FORMYLATED N-HETEROCYCLIC DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2018-01-31 | — | — | EP | disclosed |
| WO-2016151499-A1 | FORMYLATED N-HETEROCYCLIC DERIVATIVES AS FGFR4 INHIBITORS | NOVARTIS AG (CH) | 2016-09-29 | — | — | WO | disclosed |
| CN-104755465-A | Heterocyclic compounds | TAKEDA PHARMACEUTICAL | 2015-07-01 | — | — | CN | disclosed |
| WO-2008119569-A1 | SYNTHESIS OF ANTHRANILAMIDES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-10-09 | — | — | WO | disclosed |
| US-20080242866-A1 | SYNTHESIS OF ANTHRANILAMIDES | BAYER SCHERING PHARMA AG (DE) | 2008-10-02 | — | — | US | disclosed |
| US-20080242866-A1 | SYNTHESIS OF ANTHRANILAMIDES | BAYER SCHERING PHARMA AG (DE) | 2008-10-02 | — | — | US | disclosed |
| EP-1975166-A1 | Synthesis of anthranilamides | Bayer Schering Pharma AG (DE) | 2008-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190105309-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors. | FGFR4, FGFR1, FGFR3 | NOS3 3497/4885NOS2 3450/4885NOS1 3556/4885 |
| US-20180065951-A1 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | NOS3 3449/4885NOS2 3351/4885NOS1 3466/4885 |
| US-10189813-B2 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | NOS3 3449/4885NOS2 3351/4885NOS1 3466/4885 |
| US-10786492-B2 | Formylated N-heterocyclic derivatives as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | NOS3 3449/4885NOS2 3351/4885NOS1 3466/4885 |
| US-20080242866-A1 | SYNTHESIS OF ANTHRANILAMIDES | ANTXR2, QTRT1, NQO2 | NOS3 2078/4885NOS2 1622/4885NOS1 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.